NEWS Release

Pain Management Portfolio Expanded - First Drug License Obtained in Canada

Date: March 30, 2004

Toronto Stock Exchange Trading Symbol: WXI
http://www.wextech.ca
E-mail: wex@wextech.ca

International Wex Technologies Inc. (the "Company") is pleased to announce that Health Canada (Health Products and Food Branch) has issued Drug Identification Numbers (DIN) to the Company for topical CAPSAICIN CREAM. Drug Identification Numbers are assigned to prescription and over-the-counter drug products, and once issued, permits the manufacturer to market the drug in Canada . This important milestone marks the first product that the Company can sell in Canada , as authorized by government health officials.

Capsaicin has been found to help relieve neuralgia and pain from some arthritic conditions including osteoarthritis and rheumatoid arthritis. Neuralgia is pain, sometimes severe, that originates from the nerve endings near the surface of the skin, e.g., diabetic neuropathy, tingling and pain in the feet and toes, and pain related to shingles. Capsaicin is available in strengths of 0.025% (mild), 0.05% (regular), or 0.075% (forte) cream.

The acquisition of capsaicin cream is of particular importance to the Company. With capsaicin (a vanilloid compound for mild to moderate pain), and Tectin™ (a sodium channel blocker for moderate to severe pain), Wex will be able to provide a product for both ends of the pain spectrum while diversifying its portfolio. Furthermore, licensing agreements with a Canadian company giving Wex worldwide rights will provide the Company with a balanced product pipeline, with Capsaicin a marketed compound, while other products are still in development.

Acquisition is based on royalty payments with no "up front" financial obligations.

International Wex Technologies Inc., a publicly listed neuro-bioscience company (WXI), is focused on the development and commercialization of innovative drug products, primarily for pain management. The Company's lead compound, Tetrodotoxin, is a sodium channel blocker and is the platform for the Company's development of a portfolio of proprietary products in the field of analgesia, drug addiction withdrawal treatment, and local anaesthesia.

For additional information on our products visit us at http://www.wextech.ca or call Gordon Stanley, Corporate Communications at 604-683-8880, or at 1-800-722-7549.

Per: Donna Shum, Corporate Secretary

The Toronto Stock Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this News Release.